ACM
VTVT icon

Aisling Capital Management’s vTv Therapeutics VTVT Stock Holding History

Aisling Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.88M Buy
+50,000
New +$1.73M 0.4% 12

Other funds holding VTVT

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Aisling Capital Management's VTVT Position: Q2 2026 in Review

Aisling Capital Management opened a new position in vTv Therapeutics (VTVT) in Q2 2026: 50,000 shares worth $1.88M. The stake represents 0.4% of the portfolio and ranks #12 among its holdings.

29 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Aisling Capital Management held 50,000 shares of vTv Therapeutics worth $1.88M as of Q2 2026.
  • vTv Therapeutics was a new Aisling Capital Management position in Q2 2026.
  • vTv Therapeutics made up 0.4% of Aisling Capital Management's portfolio in Q2 2026, its #12 holding.
  • 29 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.